Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis

International Immunology

Volumn 18, Issue 9, 2006, Pages 1355-1362

  Melamed, Doron ^a   Messika, Orit ^a,b   Glass Marmor, Lea ^b   Miller, Ariel ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON RECEPTOR; CONCANAVALIN A; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GELATINASE B; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P55; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW CULTURE; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENZYME RELEASE; IMMUNOCOMPETENCE; LYMPHOCYTE SUBPOPULATION; LYMPHOPOIESIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; INTERFERON-BETA; LYMPHOPOIESIS; MATRIX METALLOPROTEINASE 9; MICE; RECEPTORS, INTERFERON; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748997048     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl068     Document Type: Article

References (54)

1. Edry, E. and Melamed, D. 2004. Receptor editing in positive and negative selection of B lymphopoiesis. J. Immunol. 173:4265.
2. Rolink, A. G., Andersson, J. and Melchers, F. 2004. Molecular mechanisms guiding late stages of B-cell development. Immunol. Rev. 197:41.
3. Shivtiel, S., Leider, N., Sadeh, O., Kraiem, Z. and Melamed, D. 2002. Impaired light chain allelic exclusion and lack of positive selection in immature B cells expressing incompetent receptor deficient of CD19. J. Immunol. 168:5596.
4. Fuentes-Panana, E. M., Bannish, G. and Monroe, J. G. 2004. Basal B-cell receptor signaling in B lymphocytes: Mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol. Rev. 197:26.
5. Loder, F., Mutschler, B., Ray, R. J. et al. 1999. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190:75.
6. Okada, T., Ngo, V. N., Ekland, E. H. et al. 2002. Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J. Exp. Med. 196:65.
7. Ma, Q., Jones, D., Borghesani, P. R. et al. 1998. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl Acad. Sci. USA 95:9448.
8. Savino, W., Mendes-Da-Cruz, D. A., Smaniotto, S., Silva-Monteiro, E. and Villa-Verde, D. M. 2004. Molecular mechanisms governing thymocyte migration: Combined role of chemokines and extracellular matrix. J. Leukoc. Biol. 75:951.
9. Young, A. J. 1999. The physiology of lymphocyte migration through the single lymph node in vivo. Semin. Immunol. 11:73.
10. Girard, J. P. and Springer, T. A. 1995. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 16:449.
11. Kunkel, E. J. and Butcher, E. C. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822.
12. St-Pierre, Y., Van Themsche, C. and Esteve, P. O. 2003. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr. Drug Targets Inflamm. Allergy 2:206.
13. Opdenakker, G., Van den Steen, P. E., Dubois, B. et al. 2001. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69:851.
14. Visse, R. and Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 92:827.
15. Woessner, J. F., Jr 1991. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:2145.
16. Goetzl, E. J., Banda, M. J. and Leppert, D. 1996. Matrix metalloproteinases in immunity. J. Immunol. 156:1.
17. Abraham, M., Shapiro, S., Karni, A., Weiner, H. L. and Miller, A. 2005. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J. Neuroimmunol. 163:157.
18. Galboiz, Y., Shapiro, S., Lahat, N. and Miller, A. 2002. Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: Implications to multiple sclerosis. J. Neuroimmunol. 131:191.
19. Abraham, M., Shapiro, S., Lahat, N. and Miller, A. 2002. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int. Immunol. 14: 1449.
20. Stefanidakis, M., Bjorklund, M., Ihanus, E., Gahmberg, C. G. and Koivunen, E. 2003. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J. Biol. Chem. 278:34674.
21. Wolf, K., Muller, R., Borgmann, S., Brocker, E. B. and Friedl, P. 2003. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 102:3262.
22. Trocme, C., Gaudin, P., Berthier, S., Barro, C., Zaoui, P. and Morel, F. 1998. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J. Biol. Chem. 273:20677.
23. Di Girolamo, N., Tedla, N., Lloyd, A. and Wakefield, D. 1998. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur. J. Immunol. 28:1773.
24. Bauvois, B., Dumont, J., Mathiot, C. and Kolb, J. P. 2002. Production of matrix metalloproteinase-9 in early stage B-CLL: Suppression by interferons. Leukemia 16:791.
25. Kuwata, N., Igarashi, H., Ohmura, T., Aizawa, S. and Sakaguchi, N. 1999. Cutting edge: Absence of expression of RAG1 in peritoneal B-1 cells detected by knocking into RAG1 locus with green fluorescent protein gene. J. Immunol. 163:6355.
26. Monroe, R. J., Seidl, K. J., Gaertner, F. et al. 1999. RAG2:GFP knockin mice reveal novel aspects of RAG2 expression in primary and peripheral lymphoid tissues. Immunity 11:201.
27. Yu, W., Nagaoka, H., Jankovic, M. et al. 1999. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization [see comments]. Nature 400:682.
28. Kuittinen, O., Savolainen, E. R., Koistinen, P., Mottonen, M. and Turpeenniemi-Hujanen, T. 2001. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leukoc. Res. 25:125.
29. Lin, L. I., Lin, D. T., Chang, C. J., Lee, C. Y., Tang, J. L. and Tien, H. F. 2002. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 117:835.
30. Kitamura, D., Roes, J., Kuhn, R. and Rajewsky, K. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423.
31. Melamed, D., Kench, J. A., Grabstein, K., Rolink, A. and Nemazee, D. 1997. A functional B cell receptor transgene allows efficient IL-7- independent maturation of B cell precursors. J. Immunol. 159:1233.
32. Billips, L. G., Petitte, D., Dorshkind, K., Narayanan, R., Chiu, C.-P. and Landreth, K. S. 1992. Differential roles of stromal cells, interleukin-7, and kit-ligand in the regulation of B lymphopoiesis. Blood 79:1185.
33. Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D. and Hayakawa, K. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173:1213.
34. Cumano, A., Dorshkind, K., Gillis, S. and Paige, C. J. 1990. The influence of S17 stromal cells and interleukin-7 on B cell development. Eur. J. Immunol. 20:2183.
35. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B. I. and Nagasawa, T. 2004. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20:707.
36. Heissig, B., Hattori, K., Dias, S. et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109:625.
37. Vu, T. H., Shipley, J. M., Bergers, G. et al. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411.
38. Rolink, A. G., Andersson, J. and Melchers, F. 1998. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur. J. Immunol. 28:3738.
39. Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E. and Nussenzweig, M. C. 2003. Predominant autoantibody production by early human B cell-precursors. Science 301:1374.
40. Seagal, J., Edry, E., Keren, Z., Leider, N., Benny, O., Machluf, M. and Melamed, D. 2003. A fail-safe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway. J. Exp. Med. 198:1609.
41. Mao, C., Jiang, L., Melo-Jorge, M. et al. 2004. T cell-in dependent somatic hypermutation in murine B cells with an immature phenotype. Immunity 20:133.
42. Lin, Q., Dong, C. and Cooper, M. D. 1998. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187:79.
43. Grawunder, U., Melchers, F. and Rolink, A. 1993. Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/ interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur. J. Immunol. 23:544.
44. Sedger, L. M., Hou, S., Osvath, S. R. et al. 2002. Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-alpha and lymphotoxin-alpha. J. Immunol. 169:6193.
45. Vaday, G. G. and Lider, O. 2000. Extracellular matrix moieties, cytokines, and enzymes: Dynamic effects on immune cell behavior and inflammation. J. Leukoc. Biol. 67:149.
46. Benschop, R. J., Brandl, E., Chan, A. C. and Cambier, J. C. 2001. Unique signaling properties of B cell antigen receptor in mature and immature B cells: Implications for tolerance and activation. J. Immunol. 167:4172.
47. Viau, M. and Zouali, M. 2005. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114:17.
48. Kamiguti, A. S., Lee, E. S., Till, K. J. et al. 2004. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br. J. Haematol. 125:128.
49. Sakata, K., Satoh, M., Someya, M. et al. 2004. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100:356.
50. Matache, C., Stefanescu, M., Dragomir, C. et al. 2003. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J. Autoimmun. 20:323.
51. Tchetverikov, I., Ronday, H. K., Van El, B. et al. 2004. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis. 63:881.
52. Alter, A., Duddy, M., Hebert, S. et al. 2003. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 170: 4497.
53. Galboiz, Y., Shapiro, S., Lahat, N., Rawashdeh, H. and Miller, A. 2001. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50:443.
54. Strand, S., Vollmer, P., van den Abeelen, L. et al. 2004. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23:3732.